1

Novo NordiskNovo Nordisk

A focused healthcare company A focused healthcare company

Investor PresentationInvestor Presentation

August 2002August 2002

2

Forward-looking statementsForward-looking statements

This presentation contains forward-looking statements as the term is defined in the US Private This presentation contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. Securities Litigation Reform Act of 1995.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations. Factors that may affect future This may cause actual results to differ materially from expectations. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, Novo Nordisk's ability to successfully market both new and existing of competing products, Novo Nordisk's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, unexpected growth in costs and expenses. governmental laws and related interpretation thereof, unexpected growth in costs and expenses.

Risks and uncertainties are further described in reports filed by Novo Nordisk with the US Risks and uncertainties are further described in reports filed by Novo Nordisk with the US Securities and Exchange Commission (SEC) including the company's Form 20-F, which was filed Securities and Exchange Commission (SEC) including the company's Form 20-F, which was filed on 26 April 2002. Novo Nordisk is under no duty to update any of the forward-looking statements on 26 April 2002. Novo Nordisk is under no duty to update any of the forward-looking statements after the date of this report or to conform such statements to actual results, unless required by law. after the date of this report or to conform such statements to actual results, unless required by law.

Novo Nordisk has the copyright to the information contained in this presentation. Novo Nordisk has the copyright to the information contained in this presentation. © 2002 Novo Nordisk A/S.© 2002 Novo Nordisk A/S.

3

Agenda Agenda

Update on the first half year of 2002Update on the first half year of 2002

Diabetes careDiabetes care

Haemostasis managementHaemostasis management

Growth hormone therapyGrowth hormone therapy

Hormone replacement therapyHormone replacement therapy

Financial resultsFinancial results

Outlook 2002Outlook 2002

4

First half year 2002 in briefFirst half year 2002 in brief

Sales up 6% from first half 2001Sales up 6% from first half 2001

Operating profit up 4% from first half 2001Operating profit up 4% from first half 2001

Second quarter sales up 9% and operating profit up 16% Second quarter sales up 9% and operating profit up 16%

compared to Q2 2001compared to Q2 2001

Continued depreciation of USD, JPY and GBP versus Continued depreciation of USD, JPY and GBP versus

DKKDKK

Full-year outlook maintained at 5-10% operating profit Full-year outlook maintained at 5-10% operating profit

growth growth

5

Sales by therapy first half year 2002Sales by therapy first half year 2002

Insulin sales growth in Insulin sales growth in International Operations (IO), International Operations (IO), Europe and North America. Europe and North America. NovoNormNovoNorm®® growth in Europe growth in Europe and IOand IO

North America and Europe both North America and Europe both drive growthdrive growth

Growth in Europe and the US, but Growth in Europe and the US, but Japan hit by depreciation of JPY, Japan hit by depreciation of JPY, increased competition and low increased competition and low market growthmarket growth

Negatively affected by parallel Negatively affected by parallel trade within Europe and by trade within Europe and by lower market growthlower market growth

Insulin sales growth in Insulin sales growth in International Operations (IO), International Operations (IO), Europe and North America. Europe and North America. NovoNormNovoNorm®® growth in Europe growth in Europe and IOand IO

North America and Europe both North America and Europe both drive growthdrive growth

Growth in Europe and the US, but Growth in Europe and the US, but Japan hit by depreciation of JPY, Japan hit by depreciation of JPY, increased competition and low increased competition and low market growthmarket growth

Negatively affected by parallel Negatively affected by parallel trade within Europe and by trade within Europe and by lower market growthlower market growth

Diabetes careDiabetes care

+6%+6%

Haemostasis Haemostasis managementmanagement

+15%+15%

(1%)(1%)

hGHhGH

HRTHRT(1%)

Key observations:Key observations:

Total turnover of DKK 12,035 mn: +6%Total turnover of DKK 12,035 mn: +6%

6

Key observations:Key observations:

Wea

k Q

1, b

ut

bo

th i

nsu

lin

an

d

Wea

k Q

1, b

ut

bo

th i

nsu

lin

an

d

No

voS

even

No

voS

even

®® g

row

th r

etu

rned

in

Q2

gro

wth

ret

urn

ed i

n Q

2

No

voS

even

No

voS

even

®®,

insu

lin

an

d h

GH

,

insu

lin

an

d h

GH

co

nti

nu

e to

gro

w.

con

tin

ue

to g

row

.

Gro

wth

aff

ecte

d b

y d

epre

ciat

ion

G

row

th a

ffec

ted

by

dep

reci

atio

n

of

JPY

, in

crea

sin

g c

om

pet

itio

n,

of

JPY

, in

crea

sin

g c

om

pet

itio

n,

pri

ce d

ecre

ases

an

d w

eak

pri

ce d

ecre

ases

an

d w

eak

mar

ket

dev

elo

pm

ent

mar

ket

dev

elo

pm

ent

Wea

k Q

1, b

ut

stro

ng

Q2

Wea

k Q

1, b

ut

stro

ng

Q2

gro

wth

dri

ven

by

insu

lin

an

d

gro

wth

dri

ven

by

insu

lin

an

d

ora

l an

ti-d

iab

etes

pro

du

cts

ora

l an

ti-d

iab

etes

pro

du

cts

EuropeEurope

+4%+4%

InternationalInternationalOperationsOperations

+20%+20%

North North AmericaAmerica

+10%+10%

Japan Japan & Oceania& Oceania

(4%)(4%)

Sales by region first half year 2002Sales by region first half year 2002

Total turnover of DKK 12,035 mn: +6%Total turnover of DKK 12,035 mn: +6%

7

HRTHRTGrowth hormone Growth hormone therapytherapy

Intellectual Intellectual propertyproperty

Diabetes careDiabetes care Haemostasis Haemostasis managementmanagement

PrimaryPrimarygrowth growth driversdrivers

Novo Nordisk – future key driversNovo Nordisk – future key drivers

Diabetes careDiabetes care

Secondary Secondary value value

driversdrivers

8

Diabetes care Diabetes care

SSales by quarterales by quarter

Key

ob

serv

atio

ns:

Key

ob

serv

atio

ns:

Insu

lin

gro

wth

pri

mar

ily

real

ised

in

In

suli

n g

row

th p

rim

aril

y re

alis

ed i

n

Inte

rnat

ion

al O

per

atio

ns

and

No

rth

In

tern

atio

nal

Op

erat

ion

s an

d N

ort

h

Am

eric

a, f

oll

ow

ed b

y E

uro

pe

Am

eric

a, f

oll

ow

ed b

y E

uro

pe

Jap

an &

Oce

ania

was

im

pac

ted

Ja

pan

& O

cean

ia w

as i

mp

acte

d

neg

ativ

ely

by

the

dep

reci

atio

n o

f n

egat

ivel

y b

y th

e d

epre

ciat

ion

of

JPY

an

d d

ecre

ased

sli

gh

tly

JPY

an

d d

ecre

ased

sli

gh

tly

Th

e ro

ll-o

ut

of

No

voR

apid

® a

nd

T

he

roll

-ou

t o

f N

ovo

Rap

id®

an

d

No

voM

ix®

co

nti

nu

es -

an

alo

gu

e N

ovo

Mix

® c

on

tin

ues

- a

nal

og

ue

sale

s u

p b

y 17

1% i

n 1

H 2

002

sale

s u

p b

y 17

1% i

n 1

H 2

002

No

voN

orm

®/P

ran

din

® g

row

th

No

voN

orm

®/P

ran

din

® g

row

th

dri

ven

by

Eu

rop

e an

d I

nte

rnat

ion

al

dri

ven

by

Eu

rop

e an

d I

nte

rnat

ion

al

Op

erat

ion

sO

per

atio

ns

DKK millionDKK million

1999 2000 2001 20021999 2000 2001 2002

00

500500

1,0001,000

1,5001,500

2,0002,000

2,5002,500

3,0003,000

3,5003,500

4,0004,000

4,5004,500

5,0005,000

Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2

+ 9%+ 9%

9

Insulin market overview Insulin market overview (MATQ1 2002 Volumes)(MATQ1 2002 Volumes)

Notes: Notes: Industrialised world only. Based on IMS data. Monthly data used for Canada. Industrialised world only. Based on IMS data. Monthly data used for Canada. Wal*Mart figures not included. Growth in Europe effected by conversion of Wal*Mart figures not included. Growth in Europe effected by conversion of formulation. formulation.

Novo NordiskNovo Nordiskmarket sharemarket share

2266%%

5588%%

7878%%

60%60%

4466%%World World

Rest of IMS world Rest of IMS world

Japan Japan

Europe Europe

USA USA

Market growth Market growth

4343%%

4848%%

4%4%

66%%

% market size % market size

100%100%

3.6%3.6%

7.9%7.9%

7.0%7.0%

7.8%7.8%

6.1%6.1%

10

’’In-market’ salesIn-market’ sales

Growth compared to previous yearsGrowth compared to previous years

Q2 Q2 20012001

Q3 Q3 20012001

Q4Q420012001

Jan/Feb Jan/Feb 20022002

Q1 Q1 20022002

YTD YTD May May 20022002

Total market growth:Total market growth:

VolumeVolume

ValueValue

9%9%

13%13%

9%9%

11%11%

9%9%

13%13%

8%8%

12%12%

5%5%

9%9%

6%6%

10%10%

Novo Nordisk growth:Novo Nordisk growth:

VolumeVolume

ValueValue

9%9%

11%11%

8%8%

9%9%

9%9%

12%12%

8%8%

13%13%

5%5%

10%10%

6%6%

10%10%

Insulin sales in Europe – ‘in-market’ salesInsulin sales in Europe – ‘in-market’ sales

Source: Source: Based on IMS ‘brand market data’. Preliminary information for YTD May 2002Based on IMS ‘brand market data’. Preliminary information for YTD May 2002

Note: Note: ‘In market data’ reflects sale of insulin products from the wholesalers to the ‘In market data’ reflects sale of insulin products from the wholesalers to the pharmacists. pharmacists.

11

European analogue conversion - NovoRapidEuropean analogue conversion - NovoRapid®®

Short-acting segment in EuropeShort-acting segment in Europe

Q2 1996Q2 1996 Q1 2002Q1 2002

Short-acting human insulinShort-acting human insulin

37%37%Short-actingShort-acting

insulin analoguesinsulin analogues

Short-acting human insulinShort-acting human insulin

June 2000June 2000

NovoRapidNovoRapid®® market market share 12.3%*share 12.3%*

Humalog market Humalog market share 26.5%*share 26.5%*

* IMS ‘brand’ volume market share of short-acting insulin. * IMS ‘brand’ volume market share of short-acting insulin. Preliminary information for Apr/May 2002Preliminary information for Apr/May 2002

Share of short-acting segmentShare of short-acting segment

May 2002May 2002

37%37%

* IMS ‘brand’ volume market share of short-acting insulin. * IMS ‘brand’ volume market share of short-acting insulin.

12

US analogue conversion - NovoLogUS analogue conversion - NovoLog®®

Key observations:Key observations:

Market share increase Market share increase backed by continued backed by continued penetration of NovoLog®penetration of NovoLog®

NovoLog® launched NovoLog® launched September 2001 - pump September 2001 - pump indication added in indication added in December 2001December 2001

Launch of NovoLogLaunch of NovoLog®®Mix to Mix to follow this yearfollow this year0%0%

5%5%

10%10%

15%15%

20%20%

25%25%

30%30%

Q1

199

9Q

1 19

99

Q2

199

9Q

2 19

99

Q3

199

9Q

3 19

99

Q4

199

9Q

4 19

99

Q1

200

0Q

1 20

00

Q2

200

0Q

2 20

00

Q3

200

0Q

3 20

00

Q4

200

0Q

4 20

00

Q1

200

1Q

1 20

01

Q2

200

1Q

2 20

01

Q3

200

1Q

3 20

01

Q4

200

1Q

4 20

01

Q1

200

2Q

1 20

02

Novo Nordisk total market share (vol) in the USNovo Nordisk total market share (vol) in the US

NovoLogNovoLog® share® share

Novo Nordisk share of the Novo Nordisk share of the US short-acting marketUS short-acting market

13

NovoMixNovoMix® ® 30 – simple control30 – simple control

Blood glucose controlBlood glucose control

Co

nve

nie

nce

Co

nve

nie

nce

Basal-Basal-BolusBolus

OADsOADs

Human MixHuman MixNPHNPH

NovoMix® 30NovoMix® 30

Key observations:Key observations:

NovoMixNovoMix®®30 covers the 30 covers the basal insulin need while basal insulin need while adding the benefit of adding the benefit of targeting post-prandial targeting post-prandial glucose controlglucose control

NovoMixNovoMix®®30 comes in 30 comes in FlexPenFlexPen®® - the preferred - the preferred disposable device disposable device

Full premix analogue Full premix analogue programme scheduledprogramme scheduled

14

Analogue case still intactAnalogue case still intact

Strong analogue penetration Strong analogue penetration continuescontinues

NovoRapid®/NovoLogNovoRapid®/NovoLog®® continues to increase share in the continues to increase share in the short-acting segmentshort-acting segment

NovoMixNovoMix®® 30 being rolled out in 30 being rolled out in EuropeEurope

NovoMixNovoMix® ® 30 to be launched in 30 to be launched in the US later this yearthe US later this year

Analogues backed by new Analogues backed by new devices: InDuodevices: InDuo®®, FlexPen, FlexPen®, ®, InnoLet®InnoLet® and NovoPen and NovoPen®® Jr Jr

Analogues Analogues share of insulin share of insulin sales worldwidesales worldwide

Novo Nordisk's Novo Nordisk's share of short-share of short-

acting analogue acting analogue market worldwidemarket worldwide

Notes:Notes: Volumes in industrialised world IMSVolumes in industrialised world IMS

1996 1997 1998 1999 2000 2001 2002 1996 1997 1998 1999 2000 2001 2002

17%17%

20%20%

15

The insulin business caseThe insulin business case

VolumeVolume

Number of people with diabetes Number of people with diabetes expected to double by 2025expected to double by 2025

Less than half of those affected Less than half of those affected are diagnosed are diagnosed

Ageing population and a move Ageing population and a move towards affluent lifestyle leading towards affluent lifestyle leading to increased prevalenceto increased prevalence

A drive towards intensified A drive towards intensified therapytherapy

5% annual growth5% annual growth 5% annual growth5% annual growth++

Product upgradesProduct upgrades

Conversion from human insulin Conversion from human insulin to insulin analoguesto insulin analogues

Conversion from vials and Conversion from vials and syringes to delivery systems syringes to delivery systems

16

Diabetes pipelineDiabetes pipeline

NN2211NN2211 (GLP-1 analogue)(GLP-1 analogue)

NN344NN344 (Basal analogue)(Basal analogue)

NN1998NN1998(AERx(AERx®iDMS®iDMS))

NN304NN304 (Insulin detemir) (Insulin detemir)

NN414NN414 (Beta cell rest)(Beta cell rest)

Phase 1Phase 1 Phase 2Phase 2 Phase 3Phase 3

NN2344NN2344 (Insulin sensitiser)(Insulin sensitiser)

Note: Clinical development of ragaglitazar (NN622) was suspended in July 2002. Note: Clinical development of ragaglitazar (NN622) was suspended in July 2002.

NovoMixNovoMix®® 50 50(Premixed analogue)(Premixed analogue)

17

Insulin detemir to be filed at the turn of the yearInsulin detemir to be filed at the turn of the year

Detemir compared with NPH :Detemir compared with NPH :

Has significantly less within-Has significantly less within-subject variabilitysubject variability

Results in a slight decrease in Results in a slight decrease in body weight body weight

Has significantly less nocturnal Has significantly less nocturnal hypoglycaemic eventshypoglycaemic events

Produces a smoother nocturnal Produces a smoother nocturnal glucose profileglucose profile

The duration of action of detemir The duration of action of detemir is 20 hours at a therapeutically is 20 hours at a therapeutically relevant dose of 0.4 U/kg. relevant dose of 0.4 U/kg.

CCmaxmax

CV (%)CV (%)

AUCAUC0-24h,0-24h,

CV insulin CV insulin concconc.. (%)(%)

Insulin detemirInsulin detemir 1313 2020

NPH insulinNPH insulin 2626 3737

ReductionReduction 51%51% 45%45%

p-p-valuevalue <0.001<0.001 0.0010.001

Significantly lower within-subject variabilitySignificantly lower within-subject variability

Within-subject variability of Within-subject variability of pharmacokineticspharmacokinetics

18

AERxAERx®® s.c.s.c.

Hb

AH

bA

1c1c

(%)

(%

)

HbAHbA1c1c mean profiles, ITT population, mean profiles, ITT population, mean mean ±± 2 SEM2 SEM

Our inhaled insulin – ready to enter Phase 3Our inhaled insulin – ready to enter Phase 3

77

7.57.5

88

8.58.5

99

ADA2002ADA2002

-0.74%-0.74% -0.74%-0.74%

HbAHbA1c1c(%) reduction(%) reductionKey observations:Key observations:

Deep lung deposition of aerosolsDeep lung deposition of aerosols

““Breath Check”, one unit Breath Check”, one unit increments, highly reproducible increments, highly reproducible deliverydelivery

Rapid-acting profile, one unit Rapid-acting profile, one unit increments and patient-friendly increments and patient-friendly featuresfeatures

1 oral presentation and 4 posters 1 oral presentation and 4 posters at ADAat ADA

3 posters accepted for EASD3 posters accepted for EASD

Phase 3 to start later this yearPhase 3 to start later this year

19

Novo Nordisk – future key driversNovo Nordisk – future key drivers

Diabetes careDiabetes careHaemostasisHaemostasismanagementmanagement

PrimaryPrimarygrowth growth driversdrivers

Secondary Secondary valuevalue

driversdrivers HRTHRT Intellectual Intellectual

propertypropertyGrowth hormone Growth hormone

therapytherapy

20

Haemostasis management (NovoSevenHaemostasis management (NovoSeven®®) )

Ke

y o

bse

rva

tion

s:K

ey

obs

erv

atio

ns:

Gro

wth

in N

ort

h A

me

rica

G

row

th in

No

rth

Am

eric

a

con

tinu

es

con

tinu

es

So

lid Q

2 g

row

th in

Eu

rop

e,

So

lid Q

2 g

row

th in

Eu

rop

e,

par

tly d

ue

to la

rge

sin

gle

p

artly

du

e to

larg

e s

ingl

e

ord

ers

in s

eve

ral E

uro

pea

n

ord

ers

in s

eve

ral E

uro

pea

n

cou

ntr

ies

cou

ntr

ies

Pa

n E

uro

pe

an

Ha

em

ato

log

y P

an

Eu

rop

ea

n H

ae

ma

tolo

gy

Bu

sin

ess

Un

it n

ow

B

usi

nes

s U

nit

no

w

est

abl

ish

ed

est

abl

ish

ed

1999 2000 2001 20021999 2000 2001 2002

00

100100

200200

300300

400400

500500

600600

700700

800800

900900

Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2

DKK millionDKK million

SSales by quarterales by quarter

+ 20%+ 20%

21

NovoSeven® – current indicationNovoSeven® – current indication

CreateCreateconfidenceconfidence

First-lineFirst-lineposition inposition in

haemophiliahaemophilia

AcquiredAcquiredhaemophiliahaemophilia

Estimated close to Estimated close to 1,000 patients in 1,000 patients in industrialised worldindustrialised world

75-100% efficacy in 75-100% efficacy in acquired haemophiliaacquired haemophilia

Awareness creation Awareness creation and outcome dataand outcome data

~~300,000 doses with 300,000 doses with excellent safety dataexcellent safety data

Effective haemostasis Effective haemostasis established in established in orthopaedic surgeryorthopaedic surgery

Early treatment Early treatment provides faster provides faster recoveryrecovery

3,500 pts in 3,500 pts in industrialised worldindustrialised world

93% efficacy in bleeding 93% efficacy in bleeding episodes treated at homeepisodes treated at home

22

Unmet needs in haemostasis managementUnmet needs in haemostasis management

Bleeding a is serious Bleeding a is serious clinical challengeclinical challenge

Common cause of deathCommon cause of death

Morbidity associated with Morbidity associated with blood transfusions is of great blood transfusions is of great concernconcern

Alternatives are scarceAlternatives are scarce

Blood products are Blood products are becoming more scarce becoming more scarce and expensiveand expensive

Surveys indicate large Surveys indicate large unmet clinical needunmet clinical need

10 million severe bleeding 10 million severe bleeding conditions annuallyconditions annually

Severe bleeding conditions Severe bleeding conditions growing in relation to growing in relation to medical proceduresmedical procedures

Growing industry attentionGrowing industry attention

EPO manufacturersEPO manufacturers

Oxygen carriersOxygen carriers

23

Haemophilia Haemophilia & congenital & congenital

bleeding disordersbleeding disorders

NovoSeven® expansion projectNovoSeven® expansion project

Haemophilia with Haemophilia with inhibitorsinhibitors

Acquired haemophiliaAcquired haemophilia

FVII and FXI deficiencyFVII and FXI deficiency

GlanzmannGlanzmann

Bernard-SoulierBernard-Soulier

Other coagulation Other coagulation factor defectsfactor defects

Surgery & Intensive careSurgery & Intensive care

*) = Patients with chronic liver disease*) = Patients with chronic liver disease

Upper gastro-Upper gastro-intestinal bleeding *)intestinal bleeding *)

Orthotopic liver Orthotopic liver transplantation *)transplantation *)

Liver resection *)Liver resection *)

Reversal of anti-Reversal of anti-coagulation therapycoagulation therapy

Stem cell Stem cell transplantationtransplantation

Intra-cerebral Intra-cerebral bleedingsbleedings

Liver resectionLiver resection

TraumaTrauma

24

Novo Nordisk – future key driversNovo Nordisk – future key drivers

Diabetes careDiabetes carePrimaryPrimarygrowth growth driversdrivers

Secondary Secondary valuevalue

driversdrivers

Intellectual Intellectual propertyproperty HRTHRT

HaemostasisHaemostasismanagementmanagement

Growth hormone Growth hormone therapytherapy

25

Growth hormone therapyGrowth hormone therapy

DKK millionDKK million

SSales by quarterales by quarter

1999 2000 2001 20021999 2000 2001 2002

Ke

y o

bse

rva

tion

s:K

ey

obs

erv

atio

ns:

No

rditr

op

in®

Sim

ple

Xx®

stil

l N

ord

itro

pin

® S

imp

leX

x® s

till

gro

win

g in

Eu

rop

e a

nd th

e U

Sg

row

ing

in E

uro

pe

and

the

US

Gro

wth

in J

ap

an a

ffect

ed

by

Gro

wth

in J

ap

an a

ffect

ed

by

dep

reci

atio

n o

f JP

Y,

dep

reci

atio

n o

f JP

Y, a

a

ma

nd

ato

ry p

rice

red

uct

ion

as

ma

nd

ato

ry p

rice

red

uct

ion

as

we

ll a

s in

cre

ase

d co

mp

etiti

on

in

we

ll a

s in

cre

ase

d co

mp

etiti

on

in

gen

era

l and

a r

ela

tive

ly s

low

g

ene

ral a

nd a

re

lativ

ely

slo

w

ma

rke

t dev

elo

pm

en

tm

ark

et d

eve

lop

me

nt

Sa

les

an

d m

arke

ting

team

S

ale

s a

nd

mar

ketin

g te

am

und

er

rest

ruct

urin

g in

Ja

pan

und

er

rest

ruct

urin

g in

Ja

pan  

 

00

100100

200200

300300

400400

500500

600600

700700

Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2

- 1%- 1%

26

Novo Nordisk – future key driversNovo Nordisk – future key drivers

Diabetes careDiabetes carePrimaryPrimarygrowth growth driversdrivers

Secondary Secondary valuevalue

driversdrivers

Intellectual Intellectual propertyproperty

HRTHRT

HaemostasisHaemostasismanagementmanagement

Growth hormone Growth hormone therapytherapy

27

Hormone replacement therapyHormone replacement therapy

DKK millionDKK million

SSales by quarterales by quarter

1999 2000 2001 20021999 2000 2001 2002

00

5050

100100

150150

200200

250250

300300

350350

400400

450450

Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2 Q3Q3 Q4Q4 Q1Q1 Q2Q2

- 4%- 4%

Ke

y o

bse

rva

tion

s:K

ey

obs

erv

atio

ns:

Lac

k o

f gro

wth

pri

ma

rily

du

e to

L

ack

of g

row

th p

rim

ari

ly d

ue

to

incr

eas

ed

pa

ralle

l tra

de

with

in

incr

eas

ed

pa

ralle

l tra

de

with

in

Eu

rop

e, b

ut a

lso

low

er

ma

rke

t E

uro

pe

, bu

t als

o lo

we

r m

ark

et

gro

wth

gro

wth

Low

-do

se s

equ

ent

ial p

rod

uct

, L

ow-d

ose

seq

ue

ntia

l pro

du

ct,

No

vofe

mN

ovo

fem

™™, w

ill b

e la

unc

hed

in

, will

be

lau

nch

ed in

E

uro

pe

du

ring

20

02

Eu

rop

e d

uri

ng 2

00

2

Th

e te

rmin

atio

n o

f th

e W

om

en

’s

Th

e te

rmin

atio

n o

f th

e W

om

en

’s

He

alth

Initi

ativ

e st

ud

y (W

HI)

H

ea

lth In

itia

tive

stu

dy

(WH

I)

incr

eas

es

ma

rke

t unc

ert

ain

ty,

incr

eas

es

ma

rke

t unc

ert

ain

ty,

but

will

mo

st li

kely

favo

ur

but

will

mo

st li

kely

favo

ur

low

-do

se p

rodu

cts

low

-do

se p

rodu

cts

28

FFinancial resultsinancial results

Net turnoverNet turnover 12,03412,034 11,351 11,351 6 6 6,5536,553 6,0016,001 99

Operating profit Operating profit 2,8562,856 2,740 2,740 4 4 1,6061,606 1,3821,382 1616

Net financialsNet financials 99 99 241241 (59) (59) 8282 44 --

Profit before taxProfit before tax 2,9552,955 2,9812,981 (1) (1) 1,6881,688 1,3861,386 2222

Net profitNet profit 1,925 1,925 1,908 1,908 1 1 1,1011,101 887887 2424

EPS (DKK)* EPS (DKK)* 5.51 5.51 5.48 5.48 1 1 3.153.15 2.552.55 2424

* * Earnings per share on a diluted basis, ie 349.6 million shares in H1 2002 and 349.4 Earnings per share on a diluted basis, ie 349.6 million shares in H1 2002 and 349.4 million Q2 2002.million Q2 2002.

DKK millionDKK million First half year First half year Second quarter Second quarter

20022002 20012001 % change % change 20022002 20012001 % change% change

29

Currency exposureCurrency exposure

6

7

8

9

2001 avg = 8.32

2001 avg = 6.85

2000 2001 2002

Effect of 5% Effect of 5% appreciation on appreciation on

operating profit* operating profit* (DKK million)(DKK million)

JPYJPY +140+140

USDUSD +110+110

GBPGBP +50+50

* * ie before hedging activities.ie before hedging activities.

1H 2002 avg = 6.39

1H 2002 avg = 8.29

Aug 5 Apr 30DKK per USD 7.55 8.25 (8.5%)DKK per 100 JPY 6.34 6.43 (1.4%)

30

Outlook for 2002Outlook for 2002

Expected sales growth between 6-8%Expected sales growth between 6-8%

Growth in operating profit of 5-10% is reaffirmed Growth in operating profit of 5-10% is reaffirmed

Net financial income now expected to be approximately DKK Net financial income now expected to be approximately DKK 250 million250 million

Tax rate still expected at the level of 35%Tax rate still expected at the level of 35%

Investments still expected at DKK 4.5Investments still expected at DKK 4.5 billionbillion

Share repurchasing programme of DKK 2 billion initiatedShare repurchasing programme of DKK 2 billion initiated

Above outlook is based on the assumption that Above outlook is based on the assumption that exchange and interest rates remain at the current level exchange and interest rates remain at the current level (6 August 2002).(6 August 2002).

31

Investor InformationInvestor Information

Investor Relations contacts:Investor Relations contacts:

Novo Nordisk A/S Novo Nordisk A/S Investor Relations Investor Relations Novo Allé Novo Allé DK 2880 BagsværdDK 2880 BagsværdDenmark Denmark Fax (+45) 4444 2314 Fax (+45) 4444 2314

Peter HaahrPeter HaahrPhone (+45) 4442 1207Phone (+45) 4442 1207 E-mail: pehr@novonordisk.comE-mail: pehr@novonordisk.com

Palle Holm Olesen Palle Holm Olesen Phone (+45) 4442 6175Phone (+45) 4442 6175 E-mail: phoo@novonordisk.comE-mail: phoo@novonordisk.com

Rasmus JorgensenRasmus JorgensenPhonePhone (+1) 212 878 9607 (+1) 212 878 9607 E-mail: rrhj@novonordisk.comE-mail: rrhj@novonordisk.com

Share informationShare information

Novo Nordisk’sNovo Nordisk’s B shares are listed B shares are listed on the stock exchanges in on the stock exchanges in Copenhagen and London. Its Copenhagen and London. Its ADRs are listed on the New York ADRs are listed on the New York Stock Exchange under the symbol Stock Exchange under the symbol "NVO". For further company "NVO". For further company information, visit Novo Nordisk on information, visit Novo Nordisk on the Internet at the Internet at

http://www.novonordisk.comhttp://www.novonordisk.com

32

AppendixAppendix

33

SalesSales by therapy in first half year 2002 by therapy in first half year 2002

DKK millionDKK million 20022002 20012001 % of total% of total % change% change ((20022002))

Insulin etcInsulin etc 7,6117,611 7,1697,169 6363 66

OADOAD** 801801 769769 77 44

Diabetes care, totalDiabetes care, total 8,4128,412 7,9387,938 70 70 66

Haemostasis managementHaemostasis management 1,7261,726 1,4991,499 14 14 1515

Growth hormone therapyGrowth hormone therapy 998998 1,011 1,011 8 8 (1) (1)

HRTHRT 684684 692692 6 6 (1) (1)

OtherOther 214214 211211 22 11

TotalTotal 12,03412,034 11,35111,351 100100 66

* Oral antidiabetes products (OAD) include NovoNorm®/Prandin® as well as GlucoFormin* Oral antidiabetes products (OAD) include NovoNorm®/Prandin® as well as GlucoFormin® ® (generic metformin) sales by Biobrás in 1H 2002.(generic metformin) sales by Biobrás in 1H 2002.

34

Sales by region in first half year 2002Sales by region in first half year 2002

DKK millionDKK million 20022002 20012001 % of total% of total % change% change ((20022002))

Europe Europe 5,214 5,214 5,0305,030 43 43 4 4

North AmericaNorth America 2,8522,852 2,6012,601 2424 1010

Japan & OceaniaJapan & Oceania 1,9981,998 2,0792,079 17 17 (4) (4)

International OperationsInternational Operations 1,9701,970 1,6411,641 1616 2020

Total Total 12,03412,034 11,35111,351 100100 66

35

Insulin – the ultimate diabetes therapyInsulin – the ultimate diabetes therapy -

Ce

ll fu

nc

tio

n-C

ell

fun

cti

on

Diet and Diet and exercise aloneexercise alone

Oral therapyOral therapy(66%)(66%)

Insulin Insulin therapytherapy(27%)(27%)

Oral/insulinOral/insulin(approx 7%)(approx 7%)

Time from diagnosisTime from diagnosis

Type 2 - slope

Type 1 - Immediate need for Insulin

36

Improved postprandial control vs lispromix 25Improved postprandial control vs lispromix 25

0

5

10

15

20

25

Mix 25 BIAsp 30 BHI 30

-10%-10% -17%-17%

pp < 0.05 < 0.05 pp < 0.0001 < 0.0001

S-g

luco

se e

xcu

rsio

nS

-glu

cose

exc

urs

ion

0-5h

0-5h

(m

mo

l/l h

) (

mm

ol/l

h)

Hermansen K Hermansen K et al. Diabetes Careet al. Diabetes Care 2002;25:883-888. 2002;25:883-888.

37

-0.5-0.5

00

0.50.5

11

1.51.5

Insulin detemirInsulin detemir

NPHNPH

Change in Weight (Change in Weight (Kg)Kg)-1.7 Kg-1.7 Kg

E. Standl et al. Abstract number 467 ADA 2002E. Standl et al. Abstract number 467 ADA 2002

Weight change over 12 monthsWeight change over 12 months

Body weight control with insulin detemirBody weight control with insulin detemir

p = 0.002p = 0.002

Type 1 diabetesType 1 diabetes

38

Advantages of NovoSevenAdvantages of NovoSeven®®

A bleeding episode

FVIIa/NovoSeven®®

Tissue factor

Fa

ste

r h

aem

ost

asi

s le

ads

toF

ast

er

ha

emo

sta

sis

lead

s to

Fe

wer

tra

nsfu

sion

s/ tr

ans

fusi

on-

Fe

wer

tra

nsfu

sion

s/ tr

ans

fusi

on-

fre

e su

rge

ryfr

ee

surg

ery

Re

duc

ed

reb

lee

din

gR

ed

uce

d re

ble

edi

ng

Fa

ste

r re

cove

ryF

ast

er

reco

very

Re

duc

ed

mor

bid

ity a

nd m

ort

ality

Re

duc

ed

mor

bid

ity a

nd m

ort

ality

Imp

rove

d q

ual

ity o

f life

Imp

rove

d q

ual

ity o

f life

39

Corrective measures Corrective measures

Enhanced focus on analogue conversionEnhanced focus on analogue conversion

NovoRapidNovoRapid®® to be backed by NovoMix to be backed by NovoMix® 30® 30

Consolidation of European managementConsolidation of European management

Strategic changes implemented in JapanStrategic changes implemented in Japan

Dedicated cross-functional NorditropinDedicated cross-functional Norditropin®® SimpleXx SimpleXx®® sales sales

teamteam

Several upcoming clinical trialsSeveral upcoming clinical trials

Cost-containment programme targeting areas not affecting Cost-containment programme targeting areas not affecting

key production, sales or R&D activitieskey production, sales or R&D activities

Improved control measures Improved control measures

Slide from Q1 / 02 Slide from Q1 / 02 conference callconference call

40

Status on NN622 Status on NN622

Current clinical trials stopped and new planned studies Current clinical trials stopped and new planned studies postponedpostponed

Tumour mechanism studies initiatedTumour mechanism studies initiated

Several possible outcomes of mechanism studiesSeveral possible outcomes of mechanism studiesMechanism not of human relevanceMechanism not of human relevance

Mechanism of human relevanceMechanism of human relevance

Mechanism unresolvedMechanism unresolved

Renewed ragaglitazar assessment Q1 2003Renewed ragaglitazar assessment Q1 2003

The decision to suspend the clinical development of The decision to suspend the clinical development of ragaglitazar will not impact Novo Nordisk’s expectations ragaglitazar will not impact Novo Nordisk’s expectations for the financial results for 2002for the financial results for 2002

Slide from 22 July Slide from 22 July conference callconference call

41

Source: Nordea SecuritiesSource: Nordea Securities

% of 2000 sales with patents expiring in 2001-2005% of 2000 sales with patents expiring in 2001-2005

No major patent expirationsNo major patent expirations

0%0%

10%10%

20%20%

30%30%

40%40%

50%50%

60%60%

Ast

raZ

.A

stra

Z.

S-P

lou

gh

S-P

lou

gh

Mer

ckM

erck

Eli

Lill

yE

li L

illy

Pfi

zer

Pfi

zer

Ave

nti

sA

ven

tis

BM

SB

MS

GS

KG

SK

Ro

che

Ro

che

NNoo

vart

isva

rtis

Ph

arm

acia

Ph

arm

acia

J&J

J&J

AH

PA

HP

Ab

bo

ttA

bb

ott

Am

gen

Am

gen

No

vo N

ord

isk

No

vo N

ord

isk

No

sig

nif

ican

t p

aten

t ex

pir

atio

ns

No

sig

nif

ican

t p

aten

t ex

pir

atio

ns

on

th

is s

ide

of

2010

o

n t

his

sid

e o

f 20

10

42

Selected volume market share developmentSelected volume market share development

Month of Lantus Month of Lantus launchlaunch

February February 20022002

May May 20022002

USAUSA 26%26% 26%26% 27%27%

EuropeEurope 57%57% 57%57% 57%57%

GermanyGermany 44%44% 42%42% 43%43%Basal segmentBasal segment 51%51% 37%37% 36%36%

Short-actingShort-acting 42%42% 43%43% 45%45%

Mix-segmentMix-segment 43%43% 44%44% 45%45%

Source: Based on IMS data.Source: Based on IMS data.